Have a feature idea you'd love to see implemented? Let us know!

NVAX Novavax Inc

Price (delayed)

$8.94

Market cap

$1.43B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.19

Enterprise value

$1.08B

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights
Novavax's EPS has surged by 65% YoY and by 19% QoQ
Novavax's net income has increased by 48% YoY and by 3.2% from the previous quarter
NVAX's quick ratio has surged by 62% year-on-year but it is down by 9% since the previous quarter
Novavax's equity has increased by 22% YoY but it has decreased by 22% QoQ
NVAX's gross profit is down by 17% YoY and by 10% QoQ
The revenue has contracted by 16% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of NVAX
Market
Shares outstanding
160.18M
Market cap
$1.43B
Enterprise value
$1.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.22
Earnings
Revenue
$885.19M
EBIT
-$263.13M
EBITDA
-$216.36M
Free cash flow
-$112.35M
Per share
EPS
-$2.19
Free cash flow per share
-$0.7
Book value per share
-$3.29
Revenue per share
$5.53
TBVPS
$9.91
Balance sheet
Total assets
$1.71B
Total liabilities
$2.24B
Debt
$233.31M
Equity
-$526.44M
Working capital
-$77.32M
Liquidity
Debt to equity
-0.44
Current ratio
0.93
Quick ratio
0.86
Net debt/EBITDA
1.62
Margins
EBITDA margin
-24.4%
Gross margin
63.7%
Net margin
-32.2%
Operating margin
-34.1%
Efficiency
Return on assets
-17.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-49.5%
Return on sales
-29.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVAX stock price

How has the Novavax stock price performed over time
Intraday
7.71%
1 week
2.52%
1 month
-0.22%
1 year
60.22%
YTD
86.25%
QTD
-29.22%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$885.19M
Gross profit
$564.15M
Operating income
-$301.42M
Net income
-$284.86M
Gross margin
63.7%
Net margin
-32.2%
Novavax's operating income has soared by 52% YoY but it has decreased by 2.9% from the previous quarter
Novavax's net income has increased by 48% YoY and by 3.2% from the previous quarter
The operating margin has increased by 43% year-on-year but it has declined by 15% since the previous quarter
Novavax's net margin has increased by 38% YoY but it has decreased by 8% QoQ

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
1.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.22
Novavax's EPS has surged by 65% YoY and by 19% QoQ
Novavax's equity has increased by 22% YoY but it has decreased by 22% QoQ
NVAX's P/S is 87% below its 5-year quarterly average of 12.3 but 25% above its last 4 quarters average of 1.3
The revenue has contracted by 16% YoY and by 10% from the previous quarter

Efficiency

How efficient is Novavax business performance
NVAX's return on assets is up by 44% year-on-year and by 3.9% since the previous quarter
Novavax's return on sales has increased by 42% YoY but it has decreased by 7% QoQ

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 24% lower than its total liabilities
NVAX's quick ratio has surged by 62% year-on-year but it is down by 9% since the previous quarter
The current ratio has increased by 35% year-on-year but it has declined by 11% since the previous quarter
Novavax's debt is 144% higher than its equity
NVAX's debt to equity is down by 33% year-on-year but it is up by 19% since the previous quarter
Novavax's equity has increased by 22% YoY but it has decreased by 22% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.